[go: up one dir, main page]

ITMI20051630A1 - Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi - Google Patents

Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi

Info

Publication number
ITMI20051630A1
ITMI20051630A1 IT001630A ITMI20051630A ITMI20051630A1 IT MI20051630 A1 ITMI20051630 A1 IT MI20051630A1 IT 001630 A IT001630 A IT 001630A IT MI20051630 A ITMI20051630 A IT MI20051630A IT MI20051630 A1 ITMI20051630 A1 IT MI20051630A1
Authority
IT
Italy
Prior art keywords
pharmaceutical formulation
formulation containing
active principles
sterile pharmaceutical
injectable sterile
Prior art date
Application number
IT001630A
Other languages
English (en)
Inventor
Gianni Cattaneo
Leonardo Marsili
Maurizio Zenoni
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Priority to IT001630A priority Critical patent/ITMI20051630A1/it
Priority to US11/493,522 priority patent/US7964589B2/en
Priority to JP2006205688A priority patent/JP5060747B2/ja
Priority to CA002554859A priority patent/CA2554859A1/en
Priority to EP06118645A priority patent/EP1759697A1/en
Priority to KR1020060083413A priority patent/KR20070026187A/ko
Priority to CN200610126685XA priority patent/CN1923285B/zh
Publication of ITMI20051630A1 publication Critical patent/ITMI20051630A1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT001630A 2005-09-02 2005-09-02 Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi ITMI20051630A1 (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IT001630A ITMI20051630A1 (it) 2005-09-02 2005-09-02 Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
US11/493,522 US7964589B2 (en) 2005-09-02 2006-07-27 Injectable sterile pharmaceutical formulation containing at least two active principles
JP2006205688A JP5060747B2 (ja) 2005-09-02 2006-07-28 少なくとも2種の有効成分を含有する、注射可能無菌薬物配合物
CA002554859A CA2554859A1 (en) 2005-09-02 2006-07-31 A process for preparing an injectable sterile pharmaceutical formulation containing at least piperacillin sodium and tazobactam sodium active principles
EP06118645A EP1759697A1 (en) 2005-09-02 2006-08-09 Pharmaceutical formulation containing at least two active principles
KR1020060083413A KR20070026187A (ko) 2005-09-02 2006-08-31 2개 이상의 활성 물질을 함유하는 주사용 멸균 약제학적제형
CN200610126685XA CN1923285B (zh) 2005-09-02 2006-09-01 含有至少两种活性成分的注射用无菌药物制剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001630A ITMI20051630A1 (it) 2005-09-02 2005-09-02 Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi

Publications (1)

Publication Number Publication Date
ITMI20051630A1 true ITMI20051630A1 (it) 2007-03-03

Family

ID=37402634

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001630A ITMI20051630A1 (it) 2005-09-02 2005-09-02 Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi

Country Status (7)

Country Link
US (1) US7964589B2 (it)
EP (1) EP1759697A1 (it)
JP (1) JP5060747B2 (it)
KR (1) KR20070026187A (it)
CN (1) CN1923285B (it)
CA (1) CA2554859A1 (it)
IT (1) ITMI20051630A1 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20070568A1 (it) * 2007-03-22 2008-09-23 Acs Dobfar Spa Comosizione farmaceutica sterile iniettabile avente piperacillina sodica e tazobactam sodico come principi attivi
WO2013014544A1 (en) * 2011-07-25 2013-01-31 Vardhman Chemtech Limited Method for preparation of composition of piperacillin sodium and tazobactam sodium
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR101816798B1 (ko) 2012-10-19 2018-01-10 주식회사유한양행 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
EP2893929B1 (en) 2013-03-15 2025-04-16 Merck Sharp & Dohme LLC Ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN112409381B (zh) * 2020-12-03 2022-03-01 山东安信制药有限公司 一种哌拉西林钠他唑巴坦钠共无定形物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2925963A1 (de) * 1979-06-27 1981-01-22 Bayer Ag Penicillin-1,1-dioxide, ihre herstellung und ihre verwendung als arzneimittel
US4477452A (en) * 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
CA1209477A (en) * 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
CA1222691A (en) * 1981-12-29 1987-06-09 Wilhelmus T. Goedemans Method of preparing radionuclide-labelled proteins, in particular antibodies or antibody fragments
JPS58135823A (ja) * 1982-02-05 1983-08-12 Chugai Pharmaceut Co Ltd 抗生物質組成物およびその製法
IT1255716B (it) * 1992-10-05 1995-11-10 Procedimento per la preparazione di antibiotici beta-lattamici sterili
AU2003230899A1 (en) 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
PT1468697E (pt) * 2003-04-14 2008-03-05 Wyeth Corp Composições contendo piperacilina e tazobactam úteis para injecção

Also Published As

Publication number Publication date
CN1923285B (zh) 2010-06-23
JP2007070341A (ja) 2007-03-22
US20070054889A1 (en) 2007-03-08
KR20070026187A (ko) 2007-03-08
CN1923285A (zh) 2007-03-07
JP5060747B2 (ja) 2012-10-31
CA2554859A1 (en) 2007-03-02
US7964589B2 (en) 2011-06-21
EP1759697A1 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK2346495T4 (da) Farmaceutisk formulering 514
NO20075628L (no) Farmasøytiske formuleringer
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IL185390A (en) A solid dosage form
EP1984009A4 (en) PHARMACEUTICAL COMPOSITIONS WITH IMPROVED STABILITY
EP1992348A4 (en) PHARMACEUTICAL COMBINATION
DK2384754T3 (da) Farmaceutiske doseringsformer
DE602007010797D1 (de) Pharmazeutische zusammensetzungen mit rosuvastatin-calcium
RU2398586C3 (ru) Фармацевтическая композиция
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
EP2172223A4 (en) COMPOSITION CONTAINING A PHYSIOLOGICALLY ACTIVE SUBSTANCE
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0616703A2 (pt) forma de dosagem farmacêutica
ATE493119T1 (de) Pharmazeutische zusammensetzung
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
DK2001297T3 (da) Aktivstofkombinationer insekticide egenskaber
EP1987825A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR PHOSPHATE
PL1850664T3 (pl) Formulacja kapsułki pestycydowej
ITMI20050729A1 (it) Nuova formulazione biologicamente attiva
DK1957073T3 (da) Lægemiddel
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
EP1871347A4 (en) PHARMACEUTICAL COMPOSITION